Streetbeat News

Revenues

JNJ

In the last three months, 14 analysts have published ratings on Johnson & Johnson (NYSE:JNJ), with a mix of bullish and bearish perspectives. The average 12-month price target is $183.5, slightly down from the previous $185.14. Key analysts have maintained or adjusted their ratings and price targets, reflecting their views on the company's performance. Johnson & Johnson has shown solid financial performance with a 4.31% revenue growth rate, a 20.88% net margin, and a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

July 30, 2024 | 2:01 pm

HR

Analysts have mixed ratings for Healthcare Realty Trust (NYSE:HR) with a majority being indifferent. The average 12-month price target has increased to $16.33, reflecting a 4.21% rise. Financial metrics show challenges with negative revenue growth, low net margin, ROE, and ROA, but a favorable debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

July 30, 2024 | 2:01 pm

SPY

The USA JOLTs Job Openings for June came in at 8.184 million, higher than the estimated 8.020 million but slightly lower than the prior 8.230 million.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 2:00 pm

ADM

ADM CEO Luciano stated that ADM's AG Services and Oilseeds unit is in a 'transition' year due to rebalancing global supplies and demand. The unit's forecast is heavily dependent on Q4 performance, with more visibility expected as more business is directed into Q4.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 1:55 pm

PG

P&G's CFO indicated that the Middle East situation remains challenging, impacting Western retailers. The first half of fiscal 2025 is expected to mirror Q4 of fiscal 2024. P&G's premium baby care business is performing well in North America. If consumer conditions worsen, P&G expects increased demand for hand dishwashing and paper products.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 1:54 pm

ITW

Illinois Tool Works Inc. (NYSE: ITW) reported mixed Q2 2024 results, with revenue of $4.027 billion missing the consensus of $4.08 billion, but GAAP EPS of $2.54 beating the consensus of $2.47. The company revised its full-year GAAP EPS guidance to $10.30-$10.40 from $10.30-$10.70. ITW shares traded lower by 0.08% following the announcement.

Portfolio Pulse from Akanksha Bakshi

July 30, 2024 | 1:51 pm

ADM

ADM expects its Decatur East Plant to come back online in Q4. CEO Juan Luciano reports solid demand for ethanol in both domestic and export markets.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 1:48 pm

MRK

Merck's HPV vaccination activities have been impacted by China's anti-bribery and anti-corruption drive, which started last year.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 1:43 pm

FXI

MRK

Merck has reported potential shipment issues for its Gardasil vaccine in China, citing multiple factors. This could impact the company's short-term performance in the region.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 1:42 pm

ADM

ADM expects a significant decrease in FY24 operating profit for its Services & Oilseeds segment compared to the prior year. The Carbohydrate Solutions segment is expected to see a slight decrease in Q3 operating profit. However, the Nutrition segment is projected to have higher Q3 and FY24 operating profits.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 1:41 pm